Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era

•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in child...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 40; no. 22; pp. 3018 - 3026
Main Authors Shinjoh, Masayoshi, Furuichi, Munehiro, Kobayashi, Hisato, Yamaguchi, Yoshio, Maeda, Naonori, Yaginuma, Mizuki, Kobayashi, Ken, Nogayama, Taisuke, Chiga, Michiko, Oshima, Mio, Kuramochi, Yuu, Yamada, Go, Narabayashi, Atsushi, Ookawara, Ichiro, Nishida, Mitsuhiro, Tsunematsu, Kenichiro, Kamimaki, Isamu, Shimoyamada, Motoko, Yoshida, Makoto, Shibata, Akimichi, Nakata, Yuji, Taguchi, Nobuhiko, Mitamura, Keiko, Takahashi, Takao
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 11.05.2022
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in children aged 1–12. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
AbstractList Highlights•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20. •Recent inactivated flu vaccine is effective in children and infants for flu A. •Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B. •Flu vaccine effectively prevents flu A hospital admission in children aged 1–12.
BackgroundWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.MethodsThe overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons.ResultsA total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.ConclusionsThis is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.BACKGROUNDWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.METHODSThe overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.RESULTSA total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.CONCLUSIONSThis is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in children aged 1–12. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
Author Mitamura, Keiko
Oshima, Mio
Shibata, Akimichi
Kobayashi, Hisato
Shimoyamada, Motoko
Yamaguchi, Yoshio
Kuramochi, Yuu
Furuichi, Munehiro
Nakata, Yuji
Yaginuma, Mizuki
Yoshida, Makoto
Takahashi, Takao
Maeda, Naonori
Chiga, Michiko
Kamimaki, Isamu
Nishida, Mitsuhiro
Shinjoh, Masayoshi
Taguchi, Nobuhiko
Ookawara, Ichiro
Nogayama, Taisuke
Narabayashi, Atsushi
Yamada, Go
Kobayashi, Ken
Tsunematsu, Kenichiro
Author_xml – sequence: 1
  givenname: Masayoshi
  orcidid: 0000-0002-6291-7186
  surname: Shinjoh
  fullname: Shinjoh, Masayoshi
  email: m-shinjo@z2.keio.jp
  organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
– sequence: 2
  givenname: Munehiro
  orcidid: 0000-0001-7742-1135
  surname: Furuichi
  fullname: Furuichi, Munehiro
  email: furuichi-mm@keio.jp
  organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
– sequence: 3
  givenname: Hisato
  orcidid: 0000-0002-1346-6729
  surname: Kobayashi
  fullname: Kobayashi, Hisato
  email: hkobayashi1201@keio.jp
  organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
– sequence: 4
  givenname: Yoshio
  surname: Yamaguchi
  fullname: Yamaguchi, Yoshio
  email: yoyamaguchitochigimc@gmail.com
  organization: Department of Clinical Research, Department of Infection and Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomaturi, Utsunomiya-City, Tochigi 320-8580, Japan
– sequence: 5
  givenname: Naonori
  surname: Maeda
  fullname: Maeda, Naonori
  email: naonorimaeda27@gmail.com
  organization: Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan
– sequence: 6
  givenname: Mizuki
  orcidid: 0000-0002-6335-360X
  surname: Yaginuma
  fullname: Yaginuma, Mizuki
  email: yaginumamizuki@keio.jp
  organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
– sequence: 7
  givenname: Ken
  surname: Kobayashi
  fullname: Kobayashi, Ken
  email: le.petit.oeuf.26@gmail.com
  organization: Department of Pediatrics, Yokohama Municipal Citizen’s Hospital, 1-1 Mitsuzawanishimachi, Kanagawa-ku, Yokohama 221-0855, Kanagawa, Japan
– sequence: 8
  givenname: Taisuke
  surname: Nogayama
  fullname: Nogayama, Taisuke
  email: t.nogayama@keio.jp
  organization: Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan
– sequence: 9
  givenname: Michiko
  orcidid: 0000-0002-0346-9352
  surname: Chiga
  fullname: Chiga, Michiko
  email: michiko_chiga@tmhp.jp
  organization: Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan
– sequence: 10
  givenname: Mio
  orcidid: 0000-0001-9923-7347
  surname: Oshima
  fullname: Oshima, Mio
  email: mio_ooshima@tmhp.jp
  organization: Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan
– sequence: 11
  givenname: Yuu
  surname: Kuramochi
  fullname: Kuramochi, Yuu
  email: ykura123@gmail.com
  organization: Department of Pediatrics, Ota Memorial Hospital, 455-1 Ohshimacho, Ota City, Gunma 273-8585, Japan
– sequence: 12
  givenname: Go
  orcidid: 0000-0003-3122-2418
  surname: Yamada
  fullname: Yamada, Go
  email: yamago.0414time@gmail.com
  organization: Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa-shi, Chiba 272-8513, Japan
– sequence: 13
  givenname: Atsushi
  orcidid: 0000-0002-5274-8104
  surname: Narabayashi
  fullname: Narabayashi, Atsushi
  email: naraba@keio.jp
  organization: Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan
– sequence: 14
  givenname: Ichiro
  orcidid: 0000-0002-4836-1732
  surname: Ookawara
  fullname: Ookawara, Ichiro
  email: ichiro@szrc.org
  organization: Department of Pediatrics, Japanese Red Cross Shizuoka Hospital, 8-2 Outemachi, Aoi-ku, Shizuoka 420-0853, Japan
– sequence: 15
  givenname: Mitsuhiro
  orcidid: 0000-0003-2016-3598
  surname: Nishida
  fullname: Nishida, Mitsuhiro
  email: mitsumed@outlook.jp
  organization: Department of Pediatrics, Shizuoka City Shimizu Hospital, 1231 Miyakami, Shimizu-ku, Shizuoka-shi, Shizuoka 424-8636, Japan
– sequence: 16
  givenname: Kenichiro
  surname: Tsunematsu
  fullname: Tsunematsu, Kenichiro
  email: ktsune0605@yahoo.co.jp
  organization: Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0061, Japan
– sequence: 17
  givenname: Isamu
  surname: Kamimaki
  fullname: Kamimaki, Isamu
  email: kamimaki.isamu.bv@mail.hosp.go.jp
  organization: Department of Pediatrics, National Hospital Organization, Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan
– sequence: 18
  givenname: Motoko
  surname: Shimoyamada
  fullname: Shimoyamada, Motoko
  email: mochikodamochio@yahoo.co.jp
  organization: Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan
– sequence: 19
  givenname: Makoto
  orcidid: 0000-0002-2846-2069
  surname: Yoshida
  fullname: Yoshida, Makoto
  email: yoshimako0731@yahoo.co.jp
  organization: Department of Pediatrics, Sano Kosei General Hospital, 1728 Horigome-chou, Sano-city, Tochigi 327-8511, Japan
– sequence: 20
  givenname: Akimichi
  surname: Shibata
  fullname: Shibata, Akimichi
  email: helloakimichi@yahoo.co.jp
  organization: Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi 326-0843, Japan
– sequence: 21
  givenname: Yuji
  surname: Nakata
  fullname: Nakata, Yuji
  email: hihiyuji@gmail.com
  organization: Department of Pediatrics, Nippon Koukan Hospital, 1-2-1Koukan-Dori, Kawasaki, Kanagawa 210-0852, Japan
– sequence: 22
  givenname: Nobuhiko
  surname: Taguchi
  fullname: Taguchi, Nobuhiko
  email: n-taguchi@keiyu-hospital.com
  organization: Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa 220-8581, Japan
– sequence: 23
  givenname: Keiko
  surname: Mitamura
  fullname: Mitamura, Keiko
  email: mitamurakeiko77@gmail.com
  organization: Department of Pediatrics, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo 110-8645, Japan
– sequence: 24
  givenname: Takao
  orcidid: 0000-0001-9922-1775
  surname: Takahashi
  fullname: Takahashi, Takao
  email: ttakahashi@keio.jp
  organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35450780$$D View this record in MEDLINE/PubMed
BookMark eNqNUltv0zAYtdAQ6wY_AWSJF15SfEniRIgh1HGZNGkPDMSb5TifW5fULnZSqfsD_G0c2k1QCW0vvp5z_Pk75wQdOe8AoeeUTCmh5evldKO0tg6mjDA2JfmUcP4ITWgleMYKWh2hCWFlnuWUfD9GJzEuCSEFp_UTdMyLvCCiIhP06zqAayO2DoMxoHu7AQcxYm_SmRr3qoc2rU03gLtReP_syNAL27WJj5stVnPA8-CH9R-tCEkmjSp6lw5WK2ht0um2uAHjA-B-AXh29e3iPKM1hqCeosdGdRGe7edT9PXjh-vZ5-zy6tPF7P1lpgXhfcZMTTlThoNqdW2gAVI0lSBNuhBtCaVgojVAeVtXaVJVS4SomkYxqhShhp-is53uemhSURpcH1Qn18GuVNhKr6z898bZhZz7jazquuCMJYFXe4Hgfw4Qe7myUUPXKQd-iJKVJU19p2X9AGiRs7rkhUjQlwfQpR-CS50YUYLTIi9JQr34u_i7qm_tTIA3O4AOPsYARmrbq9768S-2k5TIMTxyKfcuyjE8kuQyhSexiwP27QP38d7teJCM21gIMmoLTifPQ0qUbL29V-HsQEF31lmtuh-whXjXCypj4sgvY7DHXDNGSJ7Xoytv_y_wgAJ-A3EnDSw
CitedBy_id crossref_primary_10_1097_INF_0000000000004139
crossref_primary_10_1016_j_vaccine_2024_126241
crossref_primary_10_1016_j_vaccine_2023_06_082
crossref_primary_10_36290_ped_2022_067
Cites_doi 10.2807/1560-7917.ES.2020.25.10.2000153
10.1016/j.vaccine.2017.07.003
10.1016/j.vaccine.2021.05.049
10.1016/j.celrep.2019.12.063
10.1586/14760584.2014.951036
10.1371/journal.pone.0136539
10.1371/journal.pone.0249005
10.1086/432938
10.1016/j.vaccine.2019.09.086
10.1093/infdis/jiab273
10.1016/j.vaccine.2018.07.065
10.1001/jamapediatrics.2020.0372
10.1016/j.vaccine.2019.05.090
10.1016/j.jiac.2019.08.015
10.1111/irv.12626
10.2807/1560-7917.ES.2021.26.29.2100706
10.1007/s00431-018-3145-7
10.1038/s41467-021-23440-1
10.1016/j.ijid.2020.07.032
10.1016/j.vaccine.2018.01.024
10.1016/j.jvacx.2019.100011
10.1016/j.jviromet.2013.08.018
10.1093/infdis/jiaa685
10.1093/infdis/jiaa800
10.1016/j.jiac.2021.08.020
10.1093/cid/cix312
10.15585/mmwr.rr6908a1
10.1093/cid/cir336
10.1016/j.vaccine.2020.12.012
10.2807/1560-7917.ES.2020.25.7.2000103
10.1016/j.vaccine.2010.12.049
10.7326/M17-0848
10.15585/mmwr.rr7005a1
10.1371/journal.pone.0231217
10.3390/vaccines9050415
10.1016/j.vaccine.2015.01.069
10.2807/1560-7917.ES.2019.24.4.1900055
10.1542/peds.2020-024588
ContentType Journal Article
Copyright 2022 Elsevier Ltd
Elsevier Ltd
Copyright © 2022 Elsevier Ltd. All rights reserved.
2022. Elsevier Ltd
2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd
Copyright_xml – notice: 2022 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2022 Elsevier Ltd. All rights reserved.
– notice: 2022. Elsevier Ltd
– notice: 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7RV
7T2
7T5
7U9
7X7
7XB
88C
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M0T
M1P
M2O
M7N
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
5PM
DOI 10.1016/j.vaccine.2022.04.033
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Nursing & Allied Health Database
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Healthcare Administration Database
Medical Database
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
Health & Safety Science Abstracts
ProQuest Public Health
ProQuest Central Basic
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
Research Library Prep
MEDLINE - Academic

AGRICOLA

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 3026
ExternalDocumentID PMC8995322
35450780
10_1016_j_vaccine_2022_04_033
S0264410X22004492
1_s2_0_S0264410X22004492
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
Japan
GeographicLocations_xml – name: United States--US
– name: Japan
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ABUWG
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AEXOQ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGGSO
AGUBO
AGYEJ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AQUVI
AXJTR
AZQEC
BBNVY
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CJTIS
CNWQP
CS3
DWQXO
EBS
EFJIC
EFKBS
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HMCUK
IHE
J1W
K9-
KOM
L7B
LK8
LUGTX
LW9
M0R
M0T
M1P
M29
M2O
M41
M7P
MO0
N9A
NAPCQ
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
Q38
ROL
RPZ
SAB
SCC
SDF
SDG
SDP
SES
SNL
SPCBC
SSH
SSI
SSZ
T5K
UKHRP
UV1
WH7
WOW
Z5R
~G-
.GJ
29Q
3V.
AACTN
AAQXK
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
ADVLN
AFCTW
AFJKZ
AFKWA
AGHFR
AHHHB
AJOXV
ALIPV
AMFUW
ASPBG
AVWKF
AZFZN
EJD
FEDTE
FGOYB
G-2
HEJ
HLV
HMG
HMK
HMO
HVGLF
HX~
HZ~
R2-
RIG
SAE
SEW
SIN
SVS
WUQ
XPP
ZGI
ZXP
AAIAV
AAYXX
ACMHX
ADSLC
AGQPQ
AGRNS
AGWPP
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
7XB
8FK
C1K
H94
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c703t-2f9132af3eadc9febe05b870b2f97d6e6727dfe13d98fe1a8d0778bba21aa01f3
IEDL.DBID .~1
ISSN 0264-410X
1873-2518
IngestDate Thu Aug 21 13:39:50 EDT 2025
Fri Jul 11 17:31:24 EDT 2025
Tue Aug 05 09:47:14 EDT 2025
Wed Aug 13 09:23:22 EDT 2025
Thu Apr 03 07:08:39 EDT 2025
Tue Jul 01 01:07:06 EDT 2025
Thu Apr 24 22:53:50 EDT 2025
Wed Jun 26 17:48:47 EDT 2024
Tue Feb 25 20:05:39 EST 2025
Tue Aug 26 16:34:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Vaccine
Children
Test-negative design
Influenza
COVID-19 era
Vaccine effectiveness
Language English
License Copyright © 2022 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c703t-2f9132af3eadc9febe05b870b2f97d6e6727dfe13d98fe1a8d0778bba21aa01f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2016-3598
0000-0002-6335-360X
0000-0002-5274-8104
0000-0002-4836-1732
0000-0002-6291-7186
0000-0001-9923-7347
0000-0001-7742-1135
0000-0002-0346-9352
0000-0003-3122-2418
0000-0001-9922-1775
0000-0002-1346-6729
0000-0002-2846-2069
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8995322
PMID 35450780
PQID 2657315460
PQPubID 105530
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8995322
proquest_miscellaneous_2661026169
proquest_miscellaneous_2654296357
proquest_journals_2657315460
pubmed_primary_35450780
crossref_citationtrail_10_1016_j_vaccine_2022_04_033
crossref_primary_10_1016_j_vaccine_2022_04_033
elsevier_sciencedirect_doi_10_1016_j_vaccine_2022_04_033
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X22004492
elsevier_clinicalkey_doi_10_1016_j_vaccine_2022_04_033
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-11
PublicationDateYYYYMMDD 2022-05-11
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-11
  day: 11
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Kidlington
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2022
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Shinjoh, Sugaya, Yamaguchi, Tomidokoro, Sekiguchi, Mitamura (b0045) 2015; 10
Feng, Zhang, Wang, Xie, Peng, Zheng (b0175) 2021; 12
Kowalska M, Niewiadomska E, Barański K, Kaleta-Pilarska A, Brożek G, Zejda JE. Association between influenza vaccination and positive SARS-CoV-2 IgG and IgM tests in the general population of Katowice Region, Poland. Vaccines (Basel) 2021; 9. https://doi.org10.3390/vaccines9050415.
Martin, Cheng, Petrie, Alyanak, Gaglani, Middleton (b0095) 2021; 223
World Health Organization. South-East Asia Region of WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS)
15. National Institute of Infectious Diseases. Information on epidemiology of influenza (In Japanese)
Shinjoh, Sugaya, Yamaguchi, Ookawara, Nakata, Narabayashi (b0035) 2021; 16
Fink, Orlova-Fink, Schindler, Grisi, Ferrer, Daubenberger (b0210) 2020
Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill 2020; 25.
Grohskopf, Alyanak, Ferdinands, Broder, Blanton, Talbot (b0025) 2021; 70
Sugaya, Shinjoh, Nakata, Tsunematsu, Yamaguchi, Komiyama (b0060) 2018; 36
Grohskopf, Alyanak, Broder, Blanton, Fry, Jernigan (b0040) 2020; 69
Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill 2020; 25. https://doi.org10.2807/1560-7917.Es.2020.25.10.2000153.
Cowling, Wu, Lo, Chan, Chan, Fang (b0120) 2017; 65
Sugaya, Shinjoh, Kawakami, Yamaguchi, Yoshida, Baba (b0050) 2016
Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep 2020; 30:905-13.e6. https://doi.org10.1016/j.celrep.2019.12.063.
Fukushima, Hirota (b0250) 2017; 35
6. National Institute of Infectious Diseases. Figures for National Epidemiological Surveillance of Infectious Disease (NESVPD) (In Japanese)
Feldstein, Ferdinands, Self, Randolph, Aboodi, Baughman (b0255) 2021; 224
Chung, Flannery, Gaglani, Smith, Reis, Hickey (b0130) 2020; 174
Ujiie, Tsuzuki, Nakamoto, Iwamoto (b0195) 2021; 27
Shinjoh, Sugaya, Furuichi, Araki, Maeda, Isshiki (b0065) 2019; 37
Yoshihara, Le, Toizumi, Nguyen, Vo, Odagiri (b0115) 2019; 13
Shinjoh, Furuichi, Narabayashi, Kamei, Yoshida, Takahashi (b0070) 2021
.
Katayose, Hosoya, Haneda, Yamaguchi, Kawasaki, Sato (b0105) 2011; 29
Mitamura, Shimizu, Yamazaki, Ichikawa, Abe, Yasumi (b0080) 2020; 26
National Institute of Infectious Diseases. Preliminary report of isolated virus, Infectious Agents Surveillance Report (IASR) (In Japanese)
Wall, Patel, Chung, Lee, Dawood (b0125) 2021
;
=
Sohn, Choi, Choi, Choe, Kim, Kim (b0235) 2020; 99
Jackson, Rothman (b0230) 2015; 33
Kimiya, Shinjoh, Anzo, Takahashi, Sekiguchi, Sugaya (b0135) 2018; 177
Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill 2021; 26.
Chon, Saito, Hibino, Yagami, Dapat, Odagiri (b0240) 2019; 1
Friedman, Renaud, Hines, Winter, Bolotin, Johnstone (b0020) 2019; 37
Yokohama City Institute of Public Health. Analysis of isolated influenza virus in Yokohama City in 2019/20 season (In Japanese)
Sugaya (b0015) 2014; 13
[accessed 20 September 2021].
National Institute of Infectious Diseases. Reactivity between isolated A(H1N1)pdm virus and antiserum in the 2019/20 season in Japan (In Japanese)
Merckx, Wali, Schiller, Caya, Gore, Chartrand (b0220) 2017; 167
World Health Organization. WHO public health research agenda for influenza: Optimizing treatment of patients, 2017 update.
Thangarajah, Malo, Field, Andrews, Ware, Lambert (b0110) 2021; 39
Recommendations for prevention and control of influenza in children, 2020-2021. Pediatrics 2020; 146.
Shinjoh, Sugaya, Yamaguchi, Iibuchi, Kamimaki, Goto (b0055) 2018; 36
Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill 2019; 24.
Zipfel, Colizza, Bansal (b0170) 2021; 39
Seki, Oda, Sugaya (b0090) 2020; 15
Kawai, Nanri, Ban, Inokuchi, Tanaka, Tokumura (b0010) 2011; 53
Tenforde, Talbot, Trabue, Gaglani, McNeal, Monto (b0100) 2021; 224
Sugaya, Takeuchi (b0005) 2005; 41
World Health Organization. Southern hemisphere. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS)
Patwardhan, Ohler (b0200) 2021; 13
Mitamura, Shimizu, Yamazaki, Ichikawa, Nagai, Katada (b0085) 2013; 194
10.1016/j.vaccine.2022.04.033_b0155
Fukushima (10.1016/j.vaccine.2022.04.033_b0250) 2017; 35
Chung (10.1016/j.vaccine.2022.04.033_b0130) 2020; 174
Merckx (10.1016/j.vaccine.2022.04.033_b0220) 2017; 167
Kawai (10.1016/j.vaccine.2022.04.033_b0010) 2011; 53
Shinjoh (10.1016/j.vaccine.2022.04.033_b0055) 2018; 36
Wall (10.1016/j.vaccine.2022.04.033_b0125) 2021
10.1016/j.vaccine.2022.04.033_b0160
Martin (10.1016/j.vaccine.2022.04.033_b0095) 2021; 223
Thangarajah (10.1016/j.vaccine.2022.04.033_b0110) 2021; 39
10.1016/j.vaccine.2022.04.033_b0205
Kimiya (10.1016/j.vaccine.2022.04.033_b0135) 2018; 177
10.1016/j.vaccine.2022.04.033_b0165
Sugaya (10.1016/j.vaccine.2022.04.033_b0060) 2018; 36
10.1016/j.vaccine.2022.04.033_b0245
Shinjoh (10.1016/j.vaccine.2022.04.033_b0065) 2019; 37
Sugaya (10.1016/j.vaccine.2022.04.033_b0015) 2014; 13
Friedman (10.1016/j.vaccine.2022.04.033_b0020) 2019; 37
Jackson (10.1016/j.vaccine.2022.04.033_b0230) 2015; 33
Yoshihara (10.1016/j.vaccine.2022.04.033_b0115) 2019; 13
Sugaya (10.1016/j.vaccine.2022.04.033_b0005) 2005; 41
Seki (10.1016/j.vaccine.2022.04.033_b0090) 2020; 15
Grohskopf (10.1016/j.vaccine.2022.04.033_b0040) 2020; 69
Mitamura (10.1016/j.vaccine.2022.04.033_b0085) 2013; 194
Cowling (10.1016/j.vaccine.2022.04.033_b0120) 2017; 65
Mitamura (10.1016/j.vaccine.2022.04.033_b0080) 2020; 26
Sugaya (10.1016/j.vaccine.2022.04.033_b0050) 2016
Katayose (10.1016/j.vaccine.2022.04.033_b0105) 2011; 29
Fink (10.1016/j.vaccine.2022.04.033_b0210) 2020
Sohn (10.1016/j.vaccine.2022.04.033_b0235) 2020; 99
Shinjoh (10.1016/j.vaccine.2022.04.033_b0045) 2015; 10
10.1016/j.vaccine.2022.04.033_b0215
Patwardhan (10.1016/j.vaccine.2022.04.033_b0200) 2021; 13
10.1016/j.vaccine.2022.04.033_b0140
10.1016/j.vaccine.2022.04.033_b0185
10.1016/j.vaccine.2022.04.033_b0180
Shinjoh (10.1016/j.vaccine.2022.04.033_b0035) 2021; 16
Feng (10.1016/j.vaccine.2022.04.033_b0175) 2021; 12
Feldstein (10.1016/j.vaccine.2022.04.033_b0255) 2021; 224
Zipfel (10.1016/j.vaccine.2022.04.033_b0170) 2021; 39
Tenforde (10.1016/j.vaccine.2022.04.033_b0100) 2021; 224
Ujiie (10.1016/j.vaccine.2022.04.033_b0195) 2021; 27
Shinjoh (10.1016/j.vaccine.2022.04.033_b0070) 2021
10.1016/j.vaccine.2022.04.033_b0225
10.1016/j.vaccine.2022.04.033_b0145
10.1016/j.vaccine.2022.04.033_b0150
10.1016/j.vaccine.2022.04.033_b0030
10.1016/j.vaccine.2022.04.033_b0075
10.1016/j.vaccine.2022.04.033_b0190
Grohskopf (10.1016/j.vaccine.2022.04.033_b0025) 2021; 70
Chon (10.1016/j.vaccine.2022.04.033_b0240) 2019; 1
References_xml – reference: Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill 2020; 25. https://doi.org10.2807/1560-7917.Es.2020.25.10.2000153.
– volume: 37
  start-page: 4047
  year: 2019
  end-page: 4054
  ident: b0065
  article-title: Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18
  publication-title: Vaccine
– volume: 26
  start-page: 216
  year: 2020
  end-page: 221
  ident: b0080
  article-title: Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests
  publication-title: J Infect Chemother
– volume: 224
  start-page: 813
  year: 2021
  end-page: 820
  ident: b0100
  article-title: Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020
  publication-title: J Infect Dis
– volume: 70
  start-page: 1
  year: 2021
  end-page: 28
  ident: b0025
  article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season
  publication-title: MMWR Recomm Rep
– volume: 16
  year: 2021
  ident: b0035
  article-title: Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season
  publication-title: PLoS ONE
– volume: 29
  start-page: 1844
  year: 2011
  end-page: 1849
  ident: b0105
  article-title: The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons
  publication-title: Vaccine
– reference: ;
– volume: 69
  start-page: 1
  year: 2020
  end-page: 24
  ident: b0040
  article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020–21 Influenza Season
  publication-title: MMWR Recomm Rep
– volume: 167
  start-page: 394
  year: 2017
  end-page: 409
  ident: b0220
  article-title: Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: A systematic review and meta-analysis
  publication-title: Ann Intern Med
– volume: 223
  start-page: 2062
  year: 2021
  end-page: 2071
  ident: b0095
  article-title: Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
  publication-title: J Infect Dis
– volume: 13
  start-page: 1563
  year: 2014
  end-page: 1570
  ident: b0015
  article-title: A review of the indirect protection of younger children and the elderly through a mass influenza vaccination program in Japan
  publication-title: Expert Rev Vaccines
– reference: [accessed 20 September 2021].
– volume: 99
  start-page: 199
  year: 2020
  end-page: 203
  ident: b0235
  article-title: Effectiveness of trivalent inactivated influenza vaccines in children during 2017–2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests
  publication-title: Int J Infect Dis
– volume: 36
  start-page: 5510
  year: 2018
  end-page: 5518
  ident: b0055
  article-title: Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season
  publication-title: Vaccine
– volume: 33
  start-page: 1313
  year: 2015
  end-page: 1316
  ident: b0230
  article-title: Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness
  publication-title: Vaccine
– reference: =;
– reference: National Institute of Infectious Diseases. Preliminary report of isolated virus, Infectious Agents Surveillance Report (IASR) (In Japanese),
– volume: 174
  start-page: 705
  year: 2020
  end-page: 713
  ident: b0130
  article-title: Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness
  publication-title: JAMA Pediatr
– volume: 37
  start-page: 7213
  year: 2019
  end-page: 7232
  ident: b0020
  article-title: Exploring indirect protection associated with influenza immunization - A systematic review of the literature
  publication-title: Vaccine
– reference: Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill 2019; 24.
– start-page: 21
  year: 2016
  ident: b0050
  article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season
  publication-title: Japan Euro Surveill
– year: 2021
  ident: b0070
  article-title: Risk factors in pediatric hospitalization for influenza A and B during the seven seasons immediately before the COVID-19 era in Japan
  publication-title: J Infect Chemother
– volume: 39
  start-page: 3645
  year: 2021
  end-page: 3648
  ident: b0170
  article-title: The missing season: The impacts of the COVID-19 pandemic on influenza
  publication-title: Vaccine
– year: 2020
  ident: b0210
  article-title: Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ
  publication-title: Evid Based Med
– volume: 27
  year: 2021
  ident: b0195
  article-title: Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo
  publication-title: Japan Emerg Infect Dis
– volume: 36
  start-page: 1063
  year: 2018
  end-page: 1071
  ident: b0060
  article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016
  publication-title: Vaccine
– reference: World Health Organization. South-East Asia Region of WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS),
– reference: 6. National Institute of Infectious Diseases. Figures for National Epidemiological Surveillance of Infectious Disease (NESVPD) (In Japanese),
– reference: World Health Organization. WHO public health research agenda for influenza: Optimizing treatment of patients, 2017 update.,
– reference: Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill 2020; 25.
– reference: Kowalska M, Niewiadomska E, Barański K, Kaleta-Pilarska A, Brożek G, Zejda JE. Association between influenza vaccination and positive SARS-CoV-2 IgG and IgM tests in the general population of Katowice Region, Poland. Vaccines (Basel) 2021; 9. https://doi.org10.3390/vaccines9050415.
– volume: 15
  year: 2020
  ident: b0090
  article-title: Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness
  publication-title: PLoS ONE
– volume: 39
  start-page: 729
  year: 2021
  end-page: 737
  ident: b0110
  article-title: Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018
  publication-title: Vaccine
– reference: Recommendations for prevention and control of influenza in children, 2020-2021. Pediatrics 2020; 146.
– reference: Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep 2020; 30:905-13.e6. https://doi.org10.1016/j.celrep.2019.12.063.
– volume: 65
  start-page: 300
  year: 2017
  end-page: 307
  ident: b0120
  article-title: Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004–2014
  publication-title: Clin Infect Dis
– reference: National Institute of Infectious Diseases. Reactivity between isolated A(H1N1)pdm virus and antiserum in the 2019/20 season in Japan (In Japanese)
– volume: 194
  start-page: 123
  year: 2013
  end-page: 128
  ident: b0085
  article-title: Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza
  publication-title: J Virol Methods
– volume: 13
  start-page: 248
  year: 2019
  end-page: 261
  ident: b0115
  article-title: Influenza B associated paediatric acute respiratory infection hospitalization in central Vietnam
  publication-title: Influenza Other Respir Viruses
– volume: 13
  year: 2021
  ident: b0200
  article-title: The flu vaccination may have a protective effect on the course of COVID-19 in the pediatric population: When does severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) meet influenza?
  publication-title: Cureus
– volume: 41
  start-page: 939
  year: 2005
  end-page: 947
  ident: b0005
  article-title: Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan
  publication-title: Clin Infect Dis
– reference: .
– volume: 53
  start-page: 130
  year: 2011
  end-page: 136
  ident: b0010
  article-title: Influenza vaccination of schoolchildren and influenza outbreaks in a school
  publication-title: Clin Infect Dis
– reference: Yokohama City Institute of Public Health. Analysis of isolated influenza virus in Yokohama City in 2019/20 season (In Japanese),
– volume: 10
  year: 2015
  ident: b0045
  article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results
  publication-title: PLoS ONE
– start-page: 147
  year: 2021
  ident: b0125
  article-title: Antibody response and protection after receipt of inactivated influenza vaccine: A systematic review
  publication-title: Pediatrics
– volume: 12
  start-page: 3249
  year: 2021
  ident: b0175
  article-title: Impact of COVID-19 outbreaks and interventions on influenza in China and the United States
  publication-title: Nat Commun
– volume: 1
  year: 2019
  ident: b0240
  article-title: Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation
  publication-title: Vaccine X
– reference: World Health Organization. Southern hemisphere. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS),
– volume: 35
  start-page: 4796
  year: 2017
  end-page: 4800
  ident: b0250
  article-title: Basic principles of test-negative design in evaluating influenza vaccine effectiveness
  publication-title: Vaccine
– volume: 224
  start-page: 2035
  year: 2021
  end-page: 2042
  ident: b0255
  article-title: Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates
  publication-title: J Infect Dis
– volume: 177
  start-page: 1009
  year: 2018
  end-page: 1017
  ident: b0135
  article-title: Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design
  publication-title: Eur J Pediatr
– reference: Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill 2021; 26.
– reference: 15. National Institute of Infectious Diseases. Information on epidemiology of influenza (In Japanese)
– ident: 10.1016/j.vaccine.2022.04.033_b0140
  doi: 10.2807/1560-7917.ES.2020.25.10.2000153
– volume: 35
  start-page: 4796
  year: 2017
  ident: 10.1016/j.vaccine.2022.04.033_b0250
  article-title: Basic principles of test-negative design in evaluating influenza vaccine effectiveness
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2017.07.003
– volume: 39
  start-page: 3645
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0170
  article-title: The missing season: The impacts of the COVID-19 pandemic on influenza
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.05.049
– ident: 10.1016/j.vaccine.2022.04.033_b0215
  doi: 10.1016/j.celrep.2019.12.063
– volume: 13
  start-page: 1563
  year: 2014
  ident: 10.1016/j.vaccine.2022.04.033_b0015
  article-title: A review of the indirect protection of younger children and the elderly through a mass influenza vaccination program in Japan
  publication-title: Expert Rev Vaccines
  doi: 10.1586/14760584.2014.951036
– volume: 10
  year: 2015
  ident: 10.1016/j.vaccine.2022.04.033_b0045
  article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0136539
– ident: 10.1016/j.vaccine.2022.04.033_b0155
– volume: 16
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0035
  article-title: Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0249005
– ident: 10.1016/j.vaccine.2022.04.033_b0225
– ident: 10.1016/j.vaccine.2022.04.033_b0160
– volume: 41
  start-page: 939
  year: 2005
  ident: 10.1016/j.vaccine.2022.04.033_b0005
  article-title: Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan
  publication-title: Clin Infect Dis
  doi: 10.1086/432938
– volume: 37
  start-page: 7213
  year: 2019
  ident: 10.1016/j.vaccine.2022.04.033_b0020
  article-title: Exploring indirect protection associated with influenza immunization - A systematic review of the literature
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2019.09.086
– volume: 224
  start-page: 2035
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0255
  article-title: Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiab273
– volume: 36
  start-page: 5510
  year: 2018
  ident: 10.1016/j.vaccine.2022.04.033_b0055
  article-title: Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.07.065
– volume: 174
  start-page: 705
  year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0130
  article-title: Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2020.0372
– volume: 37
  start-page: 4047
  year: 2019
  ident: 10.1016/j.vaccine.2022.04.033_b0065
  article-title: Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2019.05.090
– volume: 26
  start-page: 216
  year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0080
  article-title: Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests
  publication-title: J Infect Chemother
  doi: 10.1016/j.jiac.2019.08.015
– volume: 13
  start-page: 248
  year: 2019
  ident: 10.1016/j.vaccine.2022.04.033_b0115
  article-title: Influenza B associated paediatric acute respiratory infection hospitalization in central Vietnam
  publication-title: Influenza Other Respir Viruses
  doi: 10.1111/irv.12626
– ident: 10.1016/j.vaccine.2022.04.033_b0190
  doi: 10.2807/1560-7917.ES.2021.26.29.2100706
– volume: 177
  start-page: 1009
  year: 2018
  ident: 10.1016/j.vaccine.2022.04.033_b0135
  article-title: Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design
  publication-title: Eur J Pediatr
  doi: 10.1007/s00431-018-3145-7
– volume: 12
  start-page: 3249
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0175
  article-title: Impact of COVID-19 outbreaks and interventions on influenza in China and the United States
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-23440-1
– volume: 99
  start-page: 199
  year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0235
  article-title: Effectiveness of trivalent inactivated influenza vaccines in children during 2017–2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2020.07.032
– volume: 36
  start-page: 1063
  year: 2018
  ident: 10.1016/j.vaccine.2022.04.033_b0060
  article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.01.024
– ident: 10.1016/j.vaccine.2022.04.033_b0165
– volume: 1
  year: 2019
  ident: 10.1016/j.vaccine.2022.04.033_b0240
  article-title: Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation
  publication-title: Vaccine X
  doi: 10.1016/j.jvacx.2019.100011
– volume: 194
  start-page: 123
  year: 2013
  ident: 10.1016/j.vaccine.2022.04.033_b0085
  article-title: Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2013.08.018
– start-page: 147
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0125
  article-title: Antibody response and protection after receipt of inactivated influenza vaccine: A systematic review
  publication-title: Pediatrics
– volume: 223
  start-page: 2062
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0095
  article-title: Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa685
– volume: 224
  start-page: 813
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0100
  article-title: Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa800
– year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0070
  article-title: Risk factors in pediatric hospitalization for influenza A and B during the seven seasons immediately before the COVID-19 era in Japan
  publication-title: J Infect Chemother
  doi: 10.1016/j.jiac.2021.08.020
– volume: 65
  start-page: 300
  year: 2017
  ident: 10.1016/j.vaccine.2022.04.033_b0120
  article-title: Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004–2014
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cix312
– volume: 69
  start-page: 1
  year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0040
  article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020–21 Influenza Season
  publication-title: MMWR Recomm Rep
  doi: 10.15585/mmwr.rr6908a1
– ident: 10.1016/j.vaccine.2022.04.033_b0185
– volume: 53
  start-page: 130
  year: 2011
  ident: 10.1016/j.vaccine.2022.04.033_b0010
  article-title: Influenza vaccination of schoolchildren and influenza outbreaks in a school
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir336
– year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0210
  article-title: Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ
  publication-title: Evid Based Med
– volume: 39
  start-page: 729
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0110
  article-title: Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.12.012
– ident: 10.1016/j.vaccine.2022.04.033_b0145
  doi: 10.2807/1560-7917.ES.2020.25.7.2000103
– volume: 29
  start-page: 1844
  year: 2011
  ident: 10.1016/j.vaccine.2022.04.033_b0105
  article-title: The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.12.049
– volume: 167
  start-page: 394
  year: 2017
  ident: 10.1016/j.vaccine.2022.04.033_b0220
  article-title: Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: A systematic review and meta-analysis
  publication-title: Ann Intern Med
  doi: 10.7326/M17-0848
– ident: 10.1016/j.vaccine.2022.04.033_b0030
– volume: 70
  start-page: 1
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0025
  article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season
  publication-title: MMWR Recomm Rep
  doi: 10.15585/mmwr.rr7005a1
– volume: 13
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0200
  article-title: The flu vaccination may have a protective effect on the course of COVID-19 in the pediatric population: When does severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) meet influenza?
  publication-title: Cureus
– volume: 15
  year: 2020
  ident: 10.1016/j.vaccine.2022.04.033_b0090
  article-title: Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0231217
– ident: 10.1016/j.vaccine.2022.04.033_b0205
  doi: 10.3390/vaccines9050415
– volume: 27
  year: 2021
  ident: 10.1016/j.vaccine.2022.04.033_b0195
  article-title: Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo
  publication-title: Japan Emerg Infect Dis
– volume: 33
  start-page: 1313
  year: 2015
  ident: 10.1016/j.vaccine.2022.04.033_b0230
  article-title: Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2015.01.069
– ident: 10.1016/j.vaccine.2022.04.033_b0150
  doi: 10.2807/1560-7917.ES.2019.24.4.1900055
– ident: 10.1016/j.vaccine.2022.04.033_b0075
– start-page: 21
  year: 2016
  ident: 10.1016/j.vaccine.2022.04.033_b0050
  article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season
  publication-title: Japan Euro Surveill
– ident: 10.1016/j.vaccine.2022.04.033_b0245
  doi: 10.1542/peds.2020-024588
– ident: 10.1016/j.vaccine.2022.04.033_b0180
SSID ssj0005319
Score 2.4070482
Snippet •Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu...
Highlights•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20. •Recent inactivated flu vaccine is effective in children and infants for...
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons....
BackgroundWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19...
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons....
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3018
SubjectTerms Adolescent
Age
Age groups
Allergy and Immunology
Case-Control Studies
Child
Child, Preschool
Children
confidence interval
Confidence intervals
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 era
COVID-19 infection
COVID-19 vaccines
Deactivation
Disease transmission
Hospitals
Humans
Immunization
Infant
Influenza
Influenza A
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B
Influenza B virus
Influenza Vaccines
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Maternal & child health
Outpatient care facilities
Patients
Seasons
Software
Test-negative design
Vaccination
Vaccine
Vaccine effectiveness
Vaccine efficacy
Vaccines
Vaccines, Inactivated
Viral diseases
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagCNQLguUVKMhIqKemtfNyfEKoUBWkQiXaam-WHTtiq5JtybbS8gf428w4TkJ5tJx2tfas43g88409D0JemdzaMpEmtlqmcaaLKgY7RMQ6N4XQFRdGY-zw3sdi9zD7MM2n4cCtDW6VvUz0gtrOKzwj30qKXKSg7wv2-vQsxqpReLsaSmjcJLcwdRlytZiK0cUj9YU9wMzI4oyz6RjBs3W8eaErvLoGEzFJfLbTNP2XbvoTe_7uQvmLTtq5R-4GMEnfdKt_n9xwzYTc7spLLifkzl64OJ-Q9f0uRfVygx6MEVftBl2n-2PyaqCZHKF_jA_SpT35A_Kjc52ls4Z2DiBBRtJ5Db9hbMQFYFYL333Jk--ahnkjRR8vTs2SgvSiPpDE_1eL6aMoHlMC79PZVx_GsnAnS2ocgGlHAZ3S7U9H79_GXFJ47IfkcOfdwfZuHEo4xBWIkkWc1BLMXV2nwLCVrIFjWG5ARBhoELZweA9sa8dTK0v40KVlQpTG6IRrzXidPiIrzbxxTwjVmQNLQFvmkgqNUiO55SIFAFMUgtUuIlm_eKoK-c2xzMaJ6h3ZjlWYu8I1VyxTsOYR2RzITrsEH9cRFD1nqD56FeStAhV0HaH4G6Frg9RoFVctdFafmUepbJqgCMtkEpFyoAzAqAM8_zPoWs-8ahhn3EsReTk0g1zByyLduPm57wNQBbMVXtUHwDeY4IWMyONuPwzvMAVoDvATRhCXdsrQAfOaX25pZl98fvNSyhz0zNOrH_0ZWcV5oicH52tkZfHt3D0HgLgwL7wU-AlRsGf9
  priority: 102
  providerName: ProQuest
Title Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X22004492
https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X22004492
https://dx.doi.org/10.1016/j.vaccine.2022.04.033
https://www.ncbi.nlm.nih.gov/pubmed/35450780
https://www.proquest.com/docview/2657315460
https://www.proquest.com/docview/2654296357
https://www.proquest.com/docview/2661026169
https://pubmed.ncbi.nlm.nih.gov/PMC8995322
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemIRAvCMpXYCAjoT0tbZwvx4-jbOpAKxVsU98sO3FEppFOtJtUHnjl3-bOcdKVAUO8JGl8F8fx-fy7-u5MyGudFEUWCu0XSkR-rNLcBzuE-yrRKVc541ph7PDhOB0dx--myXSDDNtYGHSrdLq_0elWW7s7A_c1B-dVNfgU2Lk8mIbY0bFAPRzHHKW8__2Km0dkN_dAYh-pV1E8g9P-pcpx-RrMxDC0GU-j6E_z03X8-asb5ZV5af8-uecAJd1t3vkB2TB1j9xutphc9sidQ7d43iPbkyZN9XKHHq2iruY7dJtOVgmsgad3gj4yNlCXtuwPyY_GfZZWNW2cQJyepLMS7mF8xCXg1gKu7bYn3xR17UaONmac6iUFDUZtMIl91hxTSFH8qxLkn1ZfbCjLwpwtqTYAqA0FhEqHH04O3vpMUHjtR-R4f-9oOPLdNg5-Dupk4YelAJNXlREIbS5KkJog0aAmNBTwIjW4FlyUhkWFyOCksiLgPNNahUypgJXRY7JZz2rzlFAVG7AGVBGYMEfDVAtWMB4BiElTHpTGI3HbeTJ3Oc5xq40z2TqznUrXdol9LoNYQp97pN-xnTdJPm5iSFvJkG0EK-hcCdPQTYz8d4xm7jTHXDI5B2J5Tbo9knWcawPkXyrdaoVXdvWEacIjwM9p4JFXXTHoFlwwUrWZXVgagCuYsfBvNADAwQxPhUeeNOOh-4YRwHOAoFADXxspHQHmNl8vqavPNsd5JkQCc82z_2_1c3IXf6GnB2NbZHPx9cK8AAC50C-thoAjn3I4ZkO4vrV78H40hvObvfHk408lf3b8
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEJcXBOVWGGAk2NOyxXYSxw8IoY6pZeuYxDb1zdixIzqNdJBuqPwB_g2_kWPn0o3LxsueGtU-cRwfn_Od-FwQeqFjY1IqdGCUYEGkkiwAO4QHKtYJVxnhWrnY4eF20t-L3o3i0QL62cTCOLfKRiZ6QW0mmftGvkaTmDPQ90n4-uhL4KpGudPVpoRGxRabdvYNTLby1WAd1vclpRtvd3v9oK4qEGTA3dOA5gIsMJUzeIeZyGESYayBazU0cJNYdzRpckuYESn8qNSEnKdaK0qUCknO4L5X0NWIwdZ0kem9Uy4lzBcSAbMmCiISjuYRQ2sHqycqc0flYJJS6rOrMvYvXfgn1v3dZfOUDty4jW7V4BW_qbjtDlqwRQddq8pZzjro-rA-qO-g5Z0qJfZsBe_OI7zKFbyMd-bJsoGms-_8cXxQMG7I76IflasuHhe4cjipZTKe5PCfi8U4AYxs4NqXWPmucD1vR9HEp2M9wyAtsQ9c8fcqXboq7D6Lwl7D488-bGZqD2dYWwDvFgMaxr33-4P1gAgMj30P7V3K4t5Hi8WksA8RVpEFy0OZ0NLMGcFaEEM4A8CUJDzMbRdFzeLJrM6n7sp6HMrGce5A1nOXbs1lGElY8y5abcmOqoQiFxEkDWfIJloW5LsElXcRIf8boS1rKVVKIkvoLD-EHhWHI-pEZiRoF6UtZQ3EKoD1P4MuNcwr23Hme7eLnrfNIMfc4ZQq7OTY9wFo5LIjntcHwD6Y_InoogfVfmjfIQNTAOAujMDP7JS2g8ujfralGH_y-dRTIWLQa4_Of_Rn6EZ_d7gltwbbm4_RTTdn50VCyBJanH49tk8AnE71Uy8RMPp42SLoF76Spq4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEBMvCMotMMBIsKdljeMkjh8QQi3VytioxDb1zbNjR3Qa6SDdUPkD_Cd-HcfOpRuXjZc9Nap94jg-Puc78bkg9ELFWqchV76WnPqRTDIf7BDmy1glTGaEKWljh7d3ks296N04Hi-hn00sjHWrbGSiE9R6mtlv5N0wiRkFfZ8E3bx2ixj1B6-Pv_i2gpQ9aW3KaVQssmXm38B8K18N-7DWL8Nw8Ha3t-nXFQb8DDh95oc5B2tM5hTeZ8ZzmFAQK-BgBQ1MJ8YeU-rcEKp5Cj8y1QFjqVIyJFIGJKdw32voOqMstXss7Z1xL6GuqAiYOJEfkWC8iB7qHm6cyswem4N5GoYu0yql_9KLf-Le3903z-jDwW10qway-E3FeXfQkik66EZV2nLeQSvb9aF9B62NqvTY83W8u4j2KtfxGh4tEmcDTWff-ua4AGHckN9FPyq3XTwpcOV8UstnPM3hPxuXcQp4WcO1K7fyXeJ63paiiVXHao5BcmIXxOLuVdrUVdh-IoV9hyefXQjNzBzNsTIA5A0GZIx7H_aHfZ9wDI99D-1dyeLeR8vFtDAPEZaRAStE6sCEmTWIFSeaMArgKUlYkBsPRc3iiazOrW5LfByJxonuUNRzF3bNRRAJWHMPbbRkx1VykcsIkoYzRBM5C7JegPq7jJD9jdCUtcQqBREldBYfA4eQg3FoxWfEQw-lLWUNyiqw9T-DrjbMK9pxFvvYQ8_bZpBp9qBKFmZ64voATLKZEi_qA8AfzP-Ee-hBtR_ad0jBLADoCyOwczul7WBzqp9vKSafXG71lPMYdNyjix_9GVoB4SPeD3e2HqObdsrWoYSQVbQ8-3pingBOnamnTiBgdHDVEugXba2q5A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+effectiveness+of+inactivated+influenza+vaccine+in+children+by+age+groups+in+seven+seasons+immediately+before+the+COVID-19+era&rft.jtitle=Vaccine&rft.au=Shinjoh%2C+Masayoshi&rft.au=Furuichi%2C+Munehiro&rft.au=Kobayashi%2C+Hisato&rft.au=Yamaguchi%2C+Yoshio&rft.date=2022-05-11&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=40&rft.issue=22&rft.spage=3018&rft.epage=3026&rft_id=info:doi/10.1016%2Fj.vaccine.2022.04.033&rft.externalDocID=S0264410X22004492
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X22X00212%2Fcov150h.gif